Last reviewed · How we verify
LAC triple therapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
LAC triple therapy (LAC triple therapy) — National Cancer Center, Korea. LAC triple therapy combines three agents to enhance anti-tumor immune response and inhibit cancer cell proliferation through complementary mechanisms.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LAC triple therapy TARGET | LAC triple therapy | National Cancer Center, Korea | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LAC triple therapy CI watch — RSS
- LAC triple therapy CI watch — Atom
- LAC triple therapy CI watch — JSON
- LAC triple therapy alone — RSS
Cite this brief
Drug Landscape (2026). LAC triple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/lac-triple-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing